2013-01-11 14:25:47 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Tibet Rhodiola Pharmaceutical Holding Co and produced a Rating Update Report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal – SADIF Investment Analytics, announces a new Rating Update Report covering Tibet Rhodiola Pharmaceutical Holding Co (600211). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Tibet Rhodiola Pharmaceutical Holding Co investor.
Report Summary: Tibet Rhodiola Pharmaceutical Holding Co is a below average quality company with a positive outlook. Tibet Rhodiola Pharmaceutical Holding Co has weak business growth and is run by passable management. The trend in Tibet Rhodiola Pharmaceutical Holding Co fair value exchange rate against its closest rated-competitor, Shanghai Fudan Forward S&T Co., Ltd, has been appreciating over the past 2 weeks. When compared to its closest competitor, Tibet Rhodiola Pharmaceutical Holding Co shows less overvaluation and is
equally likely to underperform the market.
The 3-page report breaks down the Total StockMark into its three components – business, management and price, performing an in-depth analysis of Tibet Rhodiola Pharmaceutical Holding Co for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 12,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.